Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a pill shield hearts from chemo damage? new study investigates

NCT ID NCT05256745

First seen Jan 09, 2026 · Last updated Jun 17, 2026 · Updated 17 times

Summary

This study tests whether a drug called azeliragon can reduce heart damage caused by chemotherapy in women with early-stage breast cancer. About 48 participants will receive azeliragon alongside their standard chemo to see if it is safe and helps protect the heart and thinking abilities. The goal is to make cancer treatment safer without interfering with its effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Georgetown Lombardi Comprehensive Cancer Center

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • John Theurer Cancer Center at Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Medstar Washington Hospital Center

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.